🇺🇸 FDA
Patent

US 11919933

Use of MYOG gene as target in preparation of drug for treating cardiomyocyte apoptosis-associated cardiovascular disease

granted A61PA61P21/00

Quick answer

US patent 11919933 (Use of MYOG gene as target in preparation of drug for treating cardiomyocyte apoptosis-associated cardiovascular disease) held by GUANGDONG BEATING ORIGIN REGENERATIVE MEDICINE CO., LTD. expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
GUANGDONG BEATING ORIGIN REGENERATIVE MEDICINE CO., LTD.
Grant date
Tue Mar 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
1
CPC classes
A61P, A61P21/00